Abstract
A remarkable advancement is been made in the treatment of cancer, through chemotherapeutic drugs like tyrosine kinase inhibitors (TKI), etc. Chemotherapy induced cutaneous side effects are multiple and usually they are underreported. Nilotinib is a second generation TKI, which is approved for imatinib resistant CML. Various cutaneous and its appendageal changes have been noticed with the use of nilotinib usage. Here, we report such case of a 34 year old male, who is a case of CML being treated with Nilotinib for 2.5 years, presented to us with perforating folliculitis, psoriasiform dermatosis, KP like lesions, madarosis and textural changes of scalp hair.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
